Original articleThe Natural History of Corticosteroid Therapy for Ulcerative Colitis in Children
Section snippets
Study Population
In January 2002, the Pediatric Inflammatory Bowel Disease Collaborative Research Group began the Pediatric Inflammatory Bowel Disease Registry, an observational research program designed to examine and characterize clinical, laboratory, and humanistic outcomes associated with current and emerging treatments in newly diagnosed pediatric patients. All patient data for the present study were accessioned from the Registry. The centers participating in the Registry prospectively record demographic,
Patients
Between January 2002 and March 2005 a total of 644 newly diagnosed children with inflammatory bowel disease were entered into the Registry. A total of 151 of these patients had a diagnosis of UC, and 97 had a minimum of 1 year of follow-up evaluation or had colectomy within the first year. Of these 97 patients, 20 (21%) did not receive corticosteroids at any time in the first year after diagnosis and 77 (79%) received corticosteroids. Demographic features of patients receiving and not receiving
Discussion
This prospective observational study shows several important differences and similarities about the use of corticosteroids for the treatment of UC in children compared with adults. Corticosteroids are used for the majority of children who are newly diagnosed with UC (79%) compared with only 34% of an inception cohort of adults in Olmsted County, Minnesota, at any time in their disease course.4 Whether this difference represents more severe disease at diagnosis in children compared with adults
References (15)
- et al.
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study
Gastroenterology
(2001) - et al.
Clinical outcome of ulcerative colitis in children
J Pediatr
(1996) - et al.
Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study
J Pediatr
(2003) - et al.
Definitions of inflammatory bowel disease of unknown etiology
Gastroenterology
(1975) - et al.
High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
Gastroenterology
(2000) - et al.
Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis
Gastroenterology
(2000) - et al.
Abnormal activation of transcription factor NF-kappaB involved in steroid resistance in chronic inflammatory bowel disease
Am J Gastroenterol
(2000)
Cited by (135)
Medical management of pediatric inflammatory bowel disease
2024, Seminars in Pediatric SurgeryInflammatory Bowel Disease: What Very Early Onset Disease Teaches Us
2018, Gastroenterology Clinics of North AmericaOral Tacrolimus in Steroid Refractory and Dependent Pediatric Ulcerative Colitis - A Systematic Review and Meta-Analysis
2023, Journal of Pediatric Gastroenterology and NutritionAnalysis of the factors influencing the efficacy of glucocorticoids in the treatment of moderate to severe pediatric ulcerative colitis
2023, Chinese Journal of Inflammatory Bowel DiseasesMedical management of pediatric inflammatory bowel disease in the Asia-Pacific region: A position paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
2023, Journal of Gastroenterology and Hepatology (Australia)
Supported by Centocor, Inc., Malvern, PA (J.H. and J.M.); Prometheus Laboratories, San Diego, CA (J.M.); Reach Out for Youth with Ileitis and Colitis, Melville, NY; and the collaborating institutions. Subra Kugathasan participated in the Advisory Board of Centocor and Abbott Laboratories. Maria Oliva-Hemker received a research grant from Centocor Inc, and is a Consultant to Abbott Immunology.